SRRK Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: Scholar Rock

Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference

17 days ago - By: Scholar Rock

Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025

23 days ago - By: Scholar Rock

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

26 days ago - By: Benzinga - Mentions: KMX SPWH

Alpha Buying: 3 Stocks With Sky-High Insider Confidence

2 months ago - By: Stocktwits - Mentions: VFMO EAOR

Scholar Rock In Spotlight After FDA Refuses To Approve Muscular Atrophy Treatment Over Third-Party Manufacturing Facility Issues

2 months ago - By: Benzinga

How Do Investors Really Feel About Scholar Rock Holding?

a month ago - By: The Motley Fool

Why Scholar Rock Stock Got Socked on Monday

a month ago - By: Stocktwits - Mentions: REGN NVO

Why Are Regeneron And Scholar Rock Shares Falling On Monday?

3 months ago - By: The Motley Fool

Scholar Rock (SRRK) Q2 Loss Widens 63%

2 months ago - By: Investor's Business Daily - Mentions: NVO

Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug

2 months ago - By: Scholar Rock

FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility

2 months ago - By: Scholar Rock

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Yahoo Finance

Scholar Rock (SRRK) Jumps 14% on Bargain-Hunting, Price Down 20.4% YTD

3 months ago - By: Scholar Rock

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Zacks Investment Research - Mentions: REGN LLY VERU

Veru Announces Novel Modified-Release Oral Formulation for Enobosarm

3 months ago - By: Scholar Rock

Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment

3 months ago - By: Yahoo Finance

Why Scholar Rock Stock Wilted on Wednesday

3 months ago - By: Scholar Rock

SCHOLAR ROCK HOLDING CORP (SRRK) Stock News

SRRK Latest News, Press Relases and Analysis

Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference

Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Alpha Buying: 3 Stocks With Sky-High Insider Confidence

Scholar Rock In Spotlight After FDA Refuses To Approve Muscular Atrophy Treatment Over Third-Party Manufacturing Facility Issues

How Do Investors Really Feel About Scholar Rock Holding?

Why Scholar Rock Stock Got Socked on Monday

Why Are Regeneron And Scholar Rock Shares Falling On Monday?

Scholar Rock (SRRK) Q2 Loss Widens 63%

Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug

FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (SRRK) Jumps 14% on Bargain-Hunting, Price Down 20.4% YTD

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Veru Announces Novel Modified-Release Oral Formulation for Enobosarm

Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment

Why Scholar Rock Stock Wilted on Wednesday

Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress